These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9724373)

  • 21. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
    PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability.
    Baer FM; Voth E; Schneider CA; Theissen P; Schicha H; Sechtem U
    Circulation; 1995 Feb; 91(4):1006-15. PubMed ID: 7850935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.
    Bader JB; Samnick S; Moringlane JR; Feiden W; Schaefer A; Kremp S; Kirsch CM
    Eur J Nucl Med; 1999 Feb; 26(2):144-51. PubMed ID: 9933348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy.
    Mortimer JE; Taylor ME
    Breast Cancer Res; 2003; 5(6):329-31. PubMed ID: 14580251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
    Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ; Hussien K; Muschel RJ
    Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning.
    Sun A; Sörensen J; Karlsson M; Turesson I; Langström B; Nilsson P; Cederblad L; Bertling J; Riklund K; Johansson S
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):651-657. PubMed ID: 17146654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
    Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
    Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours.
    Sasaki M; Kuwabara Y; Yoshida T; Nakagawa M; Fukumura T; Mihara F; Morioka T; Fukui M; Masuda K
    Eur J Nucl Med; 1998 Sep; 25(9):1261-9. PubMed ID: 9724375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.
    Yapp DT; Woo J; Kartono A; Sy J; Oliver T; Skov KA; Koch CJ; Adomat H; Dragowska WH; Fazli L; Ruth T; Adam MJ; Green D; Gleave M
    BJU Int; 2007 May; 99(5):1154-60. PubMed ID: 17309552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
    Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
    Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?
    Yen TC; Chang YC; Chan SC; Chang JT; Hsu CH; Lin KJ; Lin WJ; Fu YK; Ng SH
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):541-8. PubMed ID: 15625603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology.
    Derlon JM; Chapon F; Noël MH; Khouri S; Benali K; Petit-Taboué MC; Houtteville JP; Chajari MH; Bouvard G
    Eur J Nucl Med; 2000 Jul; 27(7):778-87. PubMed ID: 10952489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
    Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
    Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localisation of motor areas in brain tumour patients: a comparison of preoperative [18F]FDG-PET and intraoperative cortical electrostimulation.
    Schreckenberger M; Spetzger U; Sabri O; Meyer PT; Zeggel T; Zimny M; Gilsbach J; Buell U
    Eur J Nucl Med; 2001 Sep; 28(9):1394-403. PubMed ID: 11585300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.